Abstract
Contrast induced nephropathy (CIN) is a well-known and serious complication in patients with chronic renal insufficiency undergoing coronary angiography or interventions. CIN is associated with significant morbidity and mortality. This complication results in prolonged hospital stay and substantially increases the cost of medical care. Various therapeutic measures have been evaluated for the prevention of CIN. Peri-procedural saline hydration, use of low osmolality contrast agents and limiting the amount of contrast administered are the preferred methods. In recent years, the efficacy of prophylactic hemofiltration and several pharmacological agents, including low dose dopamine, theophylline, Nacetylcysteine, and fenoldopam have been evaluated in randomized controlled trials. Conflicting results, rather than convincing conclusions, were observed in the studies of most of these agents. Meta-analysis suggested that the use of Nacetylcysteine and theophylline may be able to prevent the decline of renal function after contrast exposure. This review provides an update on the recent studies in this subject as well as a critical analysis on how available evidence could be translated to daily clinical practice.
Keywords: Prevention, contrast induced nephropathy
Current Drug Therapy
Title: Prevention of Contrast Induced Nephropathy
Volume: 2 Issue: 1
Author(s): Jeffrey W.H. Fung, Cheuk C. Szeto, Leo C.C. Kum and Cheuk M. Yu
Affiliation:
Keywords: Prevention, contrast induced nephropathy
Abstract: Contrast induced nephropathy (CIN) is a well-known and serious complication in patients with chronic renal insufficiency undergoing coronary angiography or interventions. CIN is associated with significant morbidity and mortality. This complication results in prolonged hospital stay and substantially increases the cost of medical care. Various therapeutic measures have been evaluated for the prevention of CIN. Peri-procedural saline hydration, use of low osmolality contrast agents and limiting the amount of contrast administered are the preferred methods. In recent years, the efficacy of prophylactic hemofiltration and several pharmacological agents, including low dose dopamine, theophylline, Nacetylcysteine, and fenoldopam have been evaluated in randomized controlled trials. Conflicting results, rather than convincing conclusions, were observed in the studies of most of these agents. Meta-analysis suggested that the use of Nacetylcysteine and theophylline may be able to prevent the decline of renal function after contrast exposure. This review provides an update on the recent studies in this subject as well as a critical analysis on how available evidence could be translated to daily clinical practice.
Export Options
About this article
Cite this article as:
Fung W.H. Jeffrey, Szeto C. Cheuk, Kum C.C. Leo and Yu M. Cheuk, Prevention of Contrast Induced Nephropathy, Current Drug Therapy 2007; 2 (1) . https://dx.doi.org/10.2174/157488507779422365
DOI https://dx.doi.org/10.2174/157488507779422365 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
In Vitro CYP2D Inhibitory Effect and Influence on Pharmacokinetics and Pharmacodynamic Parameters of Metoprolol Succinate by Terminalia arjuna in Rats
Drug Metabolism Letters Proteinase Inhibitors: A Promising Drug Class for Treating Leishmaniasis
Current Drug Targets Clinical Significance of the Blood Pressure Changes from Day to Night
Current Hypertension Reviews Oleic Acid in Olive Oil: From a Metabolic Framework Toward a Clinical Perspective
Current Pharmaceutical Design Blood Pressure Variability/Dipper/Non-dipper in Hypertension and Diabetes
Current Hypertension Reviews A Novel Therapeutic Strategy Against Vascular Disorders with Chymase Inhibitor
Current Vascular Pharmacology Oligonucleotide-Based Molecular Therapy for Restenosis after Angioplasty
Current Drug Targets Point of NO Return for Nitrergic Nerves in Diabetes: A New Insight into Diabetic Complications
Current Pharmaceutical Design Natural Products and Cardiovascular Diseases
Current Molecular Pharmacology Combination of Therapeutic Hypothermia and Other Neuroprotective Strategies after An Ischemic Cerebral Insult
Current Neuropharmacology Blood Pressure Lowering and Outcomes in type 2 Diabetes: Implications of the Blood Pressure-Lowering Arm of the Advance Trial
Current Hypertension Reviews Ovarian Hyperstimulation Syndrome: The Best Approaches for Preven-tion and Treatment: A Mini-Review
Current Women`s Health Reviews Pulmonary Embolism Response Team (PERT) - A New Paradigm for the Treatment of Pulmonary Embolism
Current Pharmaceutical Design Exploring New CGRP Family Peptides and their Receptors in Vertebrates
Current Protein & Peptide Science Class IV Antiarrhythmic Agents: New Compounds Using an Old Strategy
Current Pharmaceutical Design Pulmonary Embolism and Pregnancy
Current Women`s Health Reviews Contemporary Treatment of Amyloid Heart Disease
Current Pharmaceutical Design Sepsis Pathophysiology and Anesthetic Consideration
Cardiovascular & Hematological Disorders-Drug Targets Some clinical applications of the electrochemical biosensors
Mini-Reviews in Medicinal Chemistry COVID-19: An Opinion of Prevention and Dietary Based Management Hypothesis
Coronaviruses